495 related articles for article (PubMed ID: 3123334)
1. Heat-treated factor VIII/von Willebrand factor concentrate in platelet-type von Willebrand's disease.
Takahashi H; Tatewaki W; Nagayama R; Hanano M; Tamura M; Yamaguchi T; Takizawa S; Wada K; Shibata A
Haemostasis; 1987; 17(6):353-60. PubMed ID: 3123334
[TBL] [Abstract][Full Text] [Related]
2. A probable double heterozygous type II von Willebrand's disease with increased ristocetin induced platelet aggregation.
Kinoshita S; Yoshioka K; Kasahara M; Takamiya O
Am J Hematol; 1992 Jul; 40(3):192-8. PubMed ID: 1609773
[TBL] [Abstract][Full Text] [Related]
3. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
Federici AB
Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
[TBL] [Abstract][Full Text] [Related]
4. Replacement therapy in platelet-type von Willebrand disease.
Takahashi H
Am J Hematol; 1985 Apr; 18(4):351-62. PubMed ID: 3919572
[TBL] [Abstract][Full Text] [Related]
5. A human myeloma-produced monoclonal protein directed against the active subpopulation of von Willebrand factor.
Bovill EG; Ershler WB; Golden EA; Tindle BH; Edson JR
Am J Clin Pathol; 1986 Jan; 85(1):115-23. PubMed ID: 3079626
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
Goudemand J; Mazurier C; Marey A; Caron C; Coupez B; Mizon P; Goudemand M
Br J Haematol; 1992 Feb; 80(2):214-21. PubMed ID: 1550779
[TBL] [Abstract][Full Text] [Related]
7. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
Brinkhous KM
Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
[TBL] [Abstract][Full Text] [Related]
8. Hemostatic effect of a heat-treated factor VIII concentrate (Haemate P) in von Willebrand's disease.
Fukui H; Nishino M; Terada S; Nishikubo T; Yoshioka A; Kinoshita S; Niinomi K; Yoshioka K
Blut; 1988 Apr; 56(4):171-8. PubMed ID: 3128354
[TBL] [Abstract][Full Text] [Related]
9. In vivo interaction of von Willebrand factor with platelets following cryoprecipitate transfusion in platelet-type von Willebrand's disease.
Miller JL; Boselli BD; Kupinski JM
Blood; 1984 Jan; 63(1):226-30. PubMed ID: 6418233
[TBL] [Abstract][Full Text] [Related]
10. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor.
Grainick HR; Williams SB; McKeown LP; Rick ME; Maisonneuve P; Jenneau C; Sultan Y
J Clin Invest; 1985 Oct; 76(4):1522-9. PubMed ID: 2932469
[TBL] [Abstract][Full Text] [Related]
11. An atypical von Willebrand's disease with hyperreactivity of platelet aggregation.
Niiya K; Kubonishi I; Taguchi H; Miyoshi I
Acta Haematol; 1984; 71(3):158-64. PubMed ID: 6424380
[TBL] [Abstract][Full Text] [Related]
12. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers.
Weiss HJ; Sussman II
Blood; 1986 Jul; 68(1):149-56. PubMed ID: 3487353
[TBL] [Abstract][Full Text] [Related]
13. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
14. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
15. Von Willebrand's disease: case report and review of literature.
Echahdi H; El Hasbaoui B; El Khorassani M; Agadr A; Khattab M
Pan Afr Med J; 2017; 27():147. PubMed ID: 28904675
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III.
Lethagen S; Berntorp E; Nilsson IM
Ann Hematol; 1992 Dec; 65(6):253-9. PubMed ID: 1457586
[TBL] [Abstract][Full Text] [Related]
17. Platelet-type von Willebrand disease platelet aggregating factor: a novel functional assay of von Willebrand factor.
Takahashi H; Tatewaki W; Hanano M; Shibata A
Thromb Res; 1987 Nov; 48(4):475-85. PubMed ID: 3127926
[TBL] [Abstract][Full Text] [Related]
18. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
19. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.
Aihara M; Kimura A; Chiba Y; Yoshida Y
Thromb Haemost; 1988 Jun; 59(3):485-90. PubMed ID: 3142084
[TBL] [Abstract][Full Text] [Related]
20. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
